Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 12, 2017 10:18:11 AM
Also, it was pointed to me "in absences of competition" a big pharma co may have the luxury to wait IPIX demands out and down, but not so much in the presence of one. Correct!
I feel that in order to shore up IPIX finances and to ensure a proper p3 trial size and execution Leo needs to partner Brilacidin. The questions then are:
Is it possible that there are more than 1 (or, yikes, 0) serious suitor?
Who might they be?
My thoughts about prospective candidates, if there are any:
Companies having a presence or potential presence (pipeline) in head and neck cancer?
Companies with concerns over declining income from their current product line?
Companies still willing to pay present (or near present) proof of concept rate for Brilacidin?
Explanation for the last point: Some companies, like Novartis, are saying that they see the current acquiring costs of proof of concept stage drugs as too high and plan to go after earlier stage, even preclinical, drug candidates: higher risk, lower cost.
Pfizer with its improving but still not very productive in-house research is perennial contestant on everything. Others?
Old geezer going off topic tangent:
It was said (with unbecoming glee, I admit) about Pfizer research when their fall from grace already had begun that they thought too much alike and somehow managed to be snobby about it. That's an ailment with no fast cure.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM